Charles Russell Speechlys make a notable entrant to several tables in AIM Advisors Guide
Charles Russell Speechlys is pleased to be ranked in a number of different tables within the AIM Advisers Rankings Guide – January 2015, including in key areas of focus Basic Materials, Consumer Services, Health Care and Technology. The merger of Charles Russell and Speechly Bircham has positioned the combined firm as a market leader in the AIM market.
Our ranking demonstrates not only our experience advising clients in the preparation for a listing but also our commitment to maintaining a strong working relationship throughout the company’s life on the public market.
Our Capital Markets expertise coupled with sector specialist Commercial advice means we are regularly seen as the go-to law firm for clients in these industries. We have seen an increase in clients requiring niche sector expertise when carrying out public market transactions and particularly value this sector specialism in the due diligence phase and in negotiating warranties in the transaction documents.
Our experience within AIM also reinforces our ability to provide a seamless service for wealthy individuals. Charles Russell Speechlys is uniquely placed to advise entrepreneurs/founders on optimising their personal wealth through tax efficient structures in preparation for a liquidity event.
Our award-winning Private Wealth group is the largest in the UK, with a key priority to protect, manage and grow business owners wealth for the future, ensuring our business advice is in line with personal objectives.
We are committed to supporting the wider quoted companies community and are active supporters of the Quoted Companies Alliance (QCA) - the only organisation dedicated to representing the interests of quoted companies outside the FTSE 350.
Our lawyers sit on a number of QCA technical committees, and work with the alliance to lobby the UK and European legislators on behalf of mid-cap and smaller companies. We are also committed to supporting SMEs gain access to finance and view our sponsorship of London Stock Exchange’s ELITE programme as a key element of this.
We continue to invest in this area and hope to enjoy further rankings in the future.
News & Insights
Are the days of botched pharmacy fraud investigations finally over?
David Reissner has reservations about a new drive to uncover community pharmacy contractor fraud...
Hacked Off about the JCT Payment Mechanisms and Adjudication?
Michael O'Connor looks at the Court of Appeal's decision in Grove Developments v S&T.